EPS growth is an important number as it gives a suggestion of the future prospects of a company. It is usually expressed as a percentage and is then referred to as the EPS growth rate. Growth in EPS is an important measure of administration performance because it shows how much money the company is making for it’s investors or shareholders, not only because of changes in profit, but also after all the effects of issuance of new shares (this is especially important when the growth comes as a result of acquisition).
Akebia Therapeutics, Inc., belongs to Healthcare sector and Biotechnology industry. The company’s Market capitalization is $485.51M with the total Outstanding Shares of 226. On 26-02-2021 (Friday), AKBA stock construct a change of -0.29 in a total of its share price and finished its trading at 3.46.
Profitability Ratios (ROE, ROA, ROI):
Looking into the profitability ratios of AKBA stock, an investor will find its ROE, ROA, ROI standing at -105.7%, -52.5% and -59.4%, respectively. Return on assets (ROA) is a financial ratio that shows the percentage of profit a company earns about its overall resources. A performance measure used to estimate the efficiency of an investment or to compare the ability of some different investments. ROI measures the amount of return on an investment relative to the investment’s cost.
Earnings per Share Details of Akebia Therapeutics, Inc.:
The EPS of AKBA is strolling at -2.97, measuring its EPS growth this year at 4.5%. As a result, the company has an EPS growth of 62% for the approaching year.
Given the significance of identifying companies that will make sure earnings per share at a tall rate, we later obsession to umpire how to identify which companies will achieve high amassing rates. One obvious showing off to identify high earnings per portion count together companies are to locate companies that have demonstrated such build up beyond the p.s. 5 to 10 years.
We can’t have sufficient maintenance the once will always replicate the difficult, but logically stocks that have grown earnings per allowance strongly in the subsequent to are a fine bet to keep on to take effect as a result.
Analyst’s mean target price for the company is $7 while analysts mean suggestion is 2.3.
A beta factor is used to measure the volatility of the stock. The stock remained 9.86% volatile for the week and 10.26% for the month.
Historical Performance In The News:
Taking a look at the performance of Akebia Therapeutics, Inc. stock, an investor will come to know that the weekly performance for this stock is valued at -22.07%, resulting in a performance for the month at -0.86%.
Therefore, the stated figure displays a quarterly performance of 12.34%, bringing six-month performance to -65.88% and year to date performance of 23.57%.
P/S, P/E, P/C and P/B/ SMA50, SMA 200:
The price-to-sales is a valuation ratio that relates a company’s stock price to its revenues. The price-to-sales ratio is a symbol of the value placed on each dollar of a company’s sales or taxes. As of now, AKBA has a P/S, P/E and P/B values of 1.58, 0 and 1.56 respectively. P/E and P/B ratios both are used on a regular basis by the investor to measure the value of the company and to get the right amount of the share.
Its P/Cash valued at 1.8. The price-to-cash-flow ratio is a stock valuation indicator that measures the value of a stock’s price to its cash flow per share
What do you mean by simple moving average (SMA)?
A simple moving average (SMA) is an arithmetic moving average calculated by adding the closing price of the security for some time periods and then dividing this total by the number of time periods. Its distance from 20-days simple moving average is -17.63%, and its distance from 50 days simple moving average is -2.22% while it has a distance of -47.08% from the 200 days simple moving average. The company’s distance from 52-week high price is 226% and while the current price is 226% from 52-week low price.